|
Baseline† clinical characteristics for all randomized women. Data are mean (SD) unless otherwise indicated |
||
| Duloxetine |
Placebo |
|
|
|
||
| Randomized N‡ |
60 |
61 |
| Age, years |
56.31 (± 11.00) |
52.59 (± 10.25) |
| BMI, kg/m2 |
24.98 (± 2.96) |
24.89 (± 3.13) |
| IEF/week (SD) [range] |
15.38 (± 9.11) [5.50–47.44] |
15.23 (± 8.74) [7.00–56.58] |
| Mean time between voids§ |
179.36 (± 38.81) |
193.32 (± 38.00) |
| I-QOL score |
61.88 (± 19.84) |
61.21 (± 22.71) |
| Previous continence surgery |
3 |
5 |
|
†Baseline is the last visit score on or prior to randomization. ‡Every randomized subject did not provide information for each variable; percentages are calculated using the number of responding women as the denominator. §P = 0.048. Abbreviations: BMI = body mass index; PFMT = pelvic floor muscle training; IEF = incontinence episode frequency; I-QOL = Incontinence Quality of Life questionnaire. | ||
Lin et al. BMC Urology 2008 8:2 doi:10.1186/1471-2490-8-2 |
||